These outcomes demonstrate the potential use of our nanoplatform as a general nanotechnology‐based strategy for cancer immunotherapy by synergizing with inhibitors of pro‐tumor TAM function and TGF‐β1 secretion to turn a highly immunosuppressive milieu into an immunoreactive TME, thereby overcoming immune tolerance. The gene discussed is TGFB1; the disease is neoplasm.